Skip to main content

Part of cannabis and investing

Aurora Cannabis Inc. said Tuesday that it “engages in exploratory discussions” with industry players but that it has not signed a deal with a beverage company for marijuana-infused drinks.

Shares of Aurora shot up 17 per cent Monday after a report by BNN Bloomberg claimed that “serious talks” had taken place between the Alberta cannabis grower and Coca-Cola Co., the Atlanta-based beverage giant.

On Tuesday, trading in Aurora’s stock was halted just after 9 a.m. to allow the company to publish a statement at the request of the Investment Industry Regulatory Organization of Canada.

Story continues below advertisement

Read more: Coca-Cola buys Australian kombucha maker Mojo

“The company’s policy is not to comment on speculative media reports,” Aurora said Tuesday in a news release that made no mention of Coca-Cola. “The company does confirm that it engages in exploratory discussions with industry participants from time to time. At this time the company confirms there is no agreement, understanding or arrangement with respect to any partnership with a beverage company.”

The use of the word “exploratory” in the statement suggests that any discussions it is having with any beverage firm are at an early stage.

Last month, The Globe and Mail first reported that Coke is among global drinks makers that have been talking to legal cannabis growers to learn more about the plant and how its legalization might impact their businesses.

Aurora has issued similar statements following news reports in the past. When The Globe first reported on May 2 that Aurora was in serious discussions to acquire rival MedReleaf Corp., Aurora issued a statement the next day similar to the one issued on Tuesday. In that release, the company didn’t use the word “exploratory” to characterize the nature of discussions. On May 14, Aurora said it had agreed to buy MedReleaf in a deal worth $3.2-billion.

In a statement on Monday, Coke said it is not interested in marijuana or cannabis, but that it is studying the market with an eye toward beverages that contain one of the main active ingredients found in cannabis: cannabidiol, or CBD. Unlike THC, this chemical does not have psychoactive effects on consumers. Instead, CBD could have possible health benefits – although clinical evidence for this is still limited at this time.

There are remaining questions about how Coke would enter the cannabis space.

Story continues below advertisement

“We have no interest in marijuana or cannabis,” Coke said Monday in its press release. “Along with many others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world. The space is evolving quickly. No decisions have been made at this time.”

Media reports Monday did not include the first line of the Coca-Cola statement.

Shares of Aurora rose 6.9 per cent by mid-day Tuesday, to $10.67.

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter